PMID- 26426520
OWN - NLM
STAT- MEDLINE
DCOM- 20160531
LR  - 20181202
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 27
IP  - 1
DP  - 2016 Jan
TI  - Comparison of the effectiveness of whole-brain radiotherapy plus temozolomide 
      versus whole-brain radiotherapy in treating brain metastases based on a 
      systematic review of randomized controlled trials.
PG  - 1-8
LID - 10.1097/CAD.0000000000000295 [doi]
AB  - Temozolomide (TMZ) combination with whole-brain radiotherapy (WBRT) has been 
      tested by many randomized controlled trials in the treatment of brain metastases 
      (BMs) in China and other countries. We performed an up-to-date meta-analysis to 
      determine (i) the log odds ratios (LORs) of objective response (ORR) and adverse 
      effects (AEs) for all-grade, and (ii) the T value of mean overall survival in 
      patients with BMs treated with WBRT combined with TMZ versus WBRT alone. PubMed, 
      Chinese National Knowledge Infrastructure, and WanFang Data were searched for 
      articles published up to 28 January 2015. Eligible studies were selected 
      according to the PRISMA statement. ORR, AEs, and 95% confidence intervals were 
      calculated using random-effects models. Eighteen studies were included in our 
      analysis. A total of 1028 participants were enrolled. Summary LORs of ORR were 
      1.0239 (P<0.0001) on comparing WBRT plus TMZ with WBRT ORR (n=17). The overall 
      mean difference of mean overall survival (n=17) between TMZ plus WBRT and WBRT 
      was 2.2505 weeks (P=0.02185). There was a significant difference between WBRT 
      plus TMZ and WBRT alone with a LOR of AEs for all-grade of (i) 0.923 for 
      gastrointestinal toxicity and (ii) 0.7978 for myelosuppression. Sensitivity 
      analysis and subgroup analysis were also performed. The 18 eligible randomized 
      controlled trials demonstrated that the combination of WBRT and TMZ significantly 
      improves the ORR and is statistically insignificant in prolonging the survival of 
      patients with BMs. In addition, an increase in the incidence of gastrointestinal 
      toxicity and myelosuppression was significant for all-grade.
FAU - Bai, Gui-Rong
AU  - Bai GR
AD  - aTasly Academy bTasly Holding Group Co. Ltd cTianjin State Key Laboratory of 
      Pharmacokinetics and Pharmacodynamics, Tianjin Institute of Pharmaceutical 
      Research, Tianjin dDepartment of Natural Science for Medicine, Peking University 
      Health Science Center, Beijing, People's Republic of China eTasly Pharmaceuticals 
      Inc., Rockville, Maryland fCellMosaic Inc., Worcester, Massachusetts, USA.
FAU - An, Jin-Bing
AU  - An JB
FAU - Chu, Yang
AU  - Chu Y
FAU - Wang, Xiang-Yang
AU  - Wang XY
FAU - Li, Shu-Ming
AU  - Li SM
FAU - Yan, Kai-Jing
AU  - Yan KJ
FAU - Lu, Fu-Rong
AU  - Lu FR
FAU - Gu, Ning
AU  - Gu N
FAU - Griffin, Amanda N
AU  - Griffin AN
FAU - Sun, Bin-Yuan
AU  - Sun BY
FAU - Li, Wei
AU  - Li W
FAU - Wang, Guo-Cheng
AU  - Wang GC
FAU - Zhou, Shui-Ping
AU  - Zhou SP
FAU - Sun, He
AU  - Sun H
FAU - Liu, Chang-Xiao
AU  - Liu CX
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/*radiotherapy/secondary
MH  - Combined Modality Therapy
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Temozolomide
EDAT- 2015/10/02 06:00
MHDA- 2016/06/01 06:00
CRDT- 2015/10/02 06:00
PHST- 2015/10/02 06:00 [entrez]
PHST- 2015/10/02 06:00 [pubmed]
PHST- 2016/06/01 06:00 [medline]
AID - 10.1097/CAD.0000000000000295 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2016 Jan;27(1):1-8. doi: 10.1097/CAD.0000000000000295.